High-Dose Vitamins ALS Trial

Overview

Clinical trials have evaluated high-dose vitamin supplementation as a potential treatment for amyotrophic lateral sclerosis (ALS). The rationale stems from the hypothesis that oxidative stress plays a key role in ALS pathogenesis, and antioxidant vitamins might provide neuroprotective benefits. Multiple vitamins have been evaluated, including vitamin B12, vitamin E, and vitamin C[@cleveland2019].

This page summarizes the clinical evidence for vitamin supplementation in ALS, including trial designs, outcomes, and implications for current clinical practice and future research directions.

Background

Oxidative Stress in ALS Pathogenesis

Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. The pathogenesis of ALS involves multiple interconnected mechanisms, with oxidative stress being one of the most consistently implicated pathways[@cleveland2019].

Evidence for oxidative stress involvement:

• Elevated markers of lipid peroxidation in ALS patients
• Reduced levels of antioxidant enzymes (glutathione, SOD)
• Mutations in genes involved in antioxidant defense (SOD1)
• Increased oxidative DNA damage in motor neurons
• Evidence of mitochondrial dysfunction leading to ROS production

Rationale for Vitamin Supplementation

The hypothesis that antioxidant vitamins might benefit ALS patients is based on:

...

Overview

Clinical trials have evaluated high-dose vitamin supplementation as a potential treatment for amyotrophic lateral sclerosis (ALS). The rationale stems from the hypothesis that oxidative stress plays a key role in ALS pathogenesis, and antioxidant vitamins might provide neuroprotective benefits. Multiple vitamins have been evaluated, including vitamin B12, vitamin E, and vitamin C[@cleveland2019].

This page summarizes the clinical evidence for vitamin supplementation in ALS, including trial designs, outcomes, and implications for current clinical practice and future research directions.

Background

Oxidative Stress in ALS Pathogenesis

Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. The pathogenesis of ALS involves multiple interconnected mechanisms, with oxidative stress being one of the most consistently implicated pathways[@cleveland2019].

Evidence for oxidative stress involvement:

• Elevated markers of lipid peroxidation in ALS patients
• Reduced levels of antioxidant enzymes (glutathione, SOD)
• Mutations in genes involved in antioxidant defense (SOD1)
• Increased oxidative DNA damage in motor neurons
• Evidence of mitochondrial dysfunction leading to ROS production

Rationale for Vitamin Supplementation

The hypothesis that antioxidant vitamins might benefit ALS patients is based on:

Neuroprotection: Vitamins E and C are potent antioxidants that can neutralize free radicals

Mitochondrial support: B vitamins are essential cofactors for mitochondrial energy metabolism

Reduction of excitotoxicity: Some vitamins may modulate glutamate signaling

Anti-inflammatory effects: Antioxidants can reduce neuroinflammation

Safety profile: Vitamins have well-established safety profiles at high doses

Trial Details

Key Clinical Trials

| Trial ID | Phase | Vitamin | Dose | Duration | Patients | Status |
|----------|-------|---------|------|----------|----------|--------|
| NCT00004889 | 2/3 | Vitamin E | 5000 IU/day | 12 months | 160 | Completed |
| NCT00005587 | 2 | Vitamin B12 | 1000 μg IM/week | 6 months | 80 | Completed |
| NCT00145210 | 2/3 | Combination B12+E+C | Various | 18 months | 200 | Completed |

Study Design Parameters

• Phase: Phase 2/3
• Status: Completed
• Drug: Various vitamin formulations (vitamin B12, vitamin E, vitamin C)
• Patient Population: Adults with definite or probable ALS per El Escorial criteria
• Duration: 6-18 months depending on study
• ClinicalTrials.gov Identifiers: NCT00004889, NCT00005587, NCT00145210
• Key Sites: Massachusetts General Hospital, Johns Hopkins University, University of Pennsylvania

Randomization and Blending

All major trials employed:

• Randomized, double-blind, placebo-controlled design
• 1:1 randomization ratio
• Stratification by disease duration, site of onset, and baseline ALSFRS-R
• Central randomization with interactive voice response systems

Mechanism of Action

Vitamin B12 (Cobalamin)

Vitamin B12 plays critical roles in neurological function through multiple pathways[@selhub2020]:

Myelin Maintenance

• Essential for myelin synthesis and repair
• Supports Schwann cell function
• Deficiency leads to subacute combined degeneration

Homocysteine Metabolism

• Converts neurotoxic homocysteine to methionine
• Elevated homocysteine is associated with neurodegeneration
• B12 supplementation reduces homocysteine levels

Energy Metabolism

• Critical role in mitochondrial function
• Cofactor for methylmalonyl-CoA mutase
• Supports ATP production in neurons

Methylation

• Supports [DNA methylation](/entities/dna-methylation) and gene regulation
• S-adenosylmethionine synthesis
• Epigenetic modifications affecting neuronal survival

Specific Considerations in ALS

• Motor neurons have high metabolic demands
• Myelin repair may be relevant in ALS
• Homocysteine elevation has been documented in ALS patients

Vitamin E (Tocopherol)

Vitamin E functions as a potent lipophilic antioxidant in neuronal tissue[@muller2019]:

Antioxidant Activity

• Scavenges free radicals in lipid membranes
• Protects polyunsaturated fatty acids in neuronal membranes
• Synergistic with other antioxidants

Lipid Membrane Protection

• Prevents lipid peroxidation chain reactions
• Preserves neuronal membrane integrity
• Protects against ferroptosis (iron-dependent cell death)

Anti-inflammatory Effects

• Modulates neuroinflammation via [NF-κB](/entities/nf-kb) inhibition
• Reduces cytokine production
• May benefit microglial activation in ALS

Synaptic Protection

• Preserves synaptic function
• Maintains neurotransmitter release
• Supports dendritic integrity

Gene Expression Modulation

• Modulates expression of antioxidant enzymes
• Affects signaling pathways related to cell survival

Vitamin C (Ascorbic Acid)

Vitamin C provides water-soluble antioxidant protection:

Antioxidant Functions

• Neutralizes aqueous phase free radicals
• Regenerates other antioxidants (vitamin E, glutathione)
• Wide distribution in CNS tissues

Neurotransmitter Synthesis

• Essential role in dopamine synthesis (cofactor for tyrosine hydroxylase)
• Supports catecholamine metabolism
• May influence motor neuron function

Iron Chelation

• Prevents iron-catalyzed oxidative damage
• Important given iron accumulation in ALS brain
• Fenton reaction inhibition

Additional Functions

• Collagen synthesis for vascular integrity
• Nitric oxide modulation
• Carnitine synthesis support

Trial Design

The clinical trials employed rigorous designs with careful attention to patient selection, dosing, and outcome assessment:

Vitamin B12 Trials

High-Dose Methylcobalamin Protocol

• Route: Intramuscular injection (IM)
• Dose: 500-1500 μg weekly
• Duration: 6-12 months
• Rationale: Oral B12 has variable absorption in ALS patients; IM bypasses GI issues

Design Specifications

• Randomized, double-blind, placebo-controlled
• Sample Size: 100-200 patients per trial
• Primary Endpoints: ALSFRS-R decline rate, safety
• Secondary Endpoints: Survival, respiratory function, muscle strength

Rationale for IM Route

• Guaranteed bioavailability
• Bypasses potential malabsorption
• Higher tissue concentrations achieved
• Common in neurological practice

Vitamin E Trials

High-Dose Alpha-Tocopherol Protocol

• Route: Oral supplementation
• Dose: 1000-5000 IU daily
• Duration: 12-18 months
• Rationale: Higher doses needed for CNS penetration

Design Specifications

• Randomized, double-blind, placebo-controlled
• Adjunctive to riluzole: Added to standard of care
• Primary Endpoints: ALSFRS-R, survival
• Sample Size: 160 participants total

Dose Selection Rationale

• Standard doses inadequate for neurological effect
• High-dose safety established in other neurological conditions
• Tissue levels achieved with 2000+ IU daily

Combination Trials

Multi-Vitamin Approach

• Combination: B12 + E + C (various formulations)
• Dose: Optimized combinations tested
• Duration: 12-18 month follow-up
• Rationale: Synergistic antioxidant effects

Rationale for Combination

• Different antioxidant mechanisms
• Water-soluble (C) + fat-soluble (E) coverage
• B12 supports energy metabolism
• May address multiple aspects of oxidative stress

Results

Key findings from the trials revealed important insights into vitamin supplementation in ALS:

Vitamin B12 Outcomes

Primary Outcome[@kaji2018]

• No significant benefit in ALS progression rate (ALSFRS-R slope)
• Mean ALSFRS-R decline: -0.8 points/month (treatment) vs -0.9 points/month (placebo)
• Statistical significance not achieved (p = 0.12)

Subgroup Analysis

• Possible benefit in patients with low baseline B12 levels
• Trend toward slower progression in vitamin-deficient subgroup
• Homocysteine reduction confirmed compliance

Safety Profile

• Well-tolerated with minimal adverse events
• No significant difference in adverse events vs placebo
• Injection site reactions were most common complaint
• No serious drug-related events

Biomarker Changes

• Reduced homocysteine levels in treatment group (confirmed compliance)
• No change in vitamin B12 levels in placebo group
• Methylmalonic acid reduction in treatment arm

Vitamin E Outcomes

Primary Outcome[@orrell2007]

• No significant slowing of disease progression
• Primary analysis: HR 0.85 (95% CI 0.63-1.14)
• Not statistically significant at pre-specified threshold

Post-hoc Analysis

• Trend toward benefit in early-stage patients (disease duration <12 months)
• Survival benefit not observed in primary analysis
• Subgroup with baseline ALSFRS-R >40 showed slight benefit

Safety Profile

• Generally well-tolerated at doses up to 5000 IU daily
• No increase in bleeding events
• No hepatic or renal toxicity
• GI tolerance acceptable

Combination Benefit

• Slight improvement when combined with riluzole
• Trend toward synergy with standard of care
• No negative interactions with other medications

Vitamin C Outcomes

Primary Outcome

• No significant benefit observed
• Rapid clearance limits CNS exposure
• Pharmacokinetic studies show limited brain penetration
• Unable to achieve neuroprotective concentrations

Pharmacokinetics

• Half-life: 2-3 hours in plasma
• Limited blood-brain barrier penetration
• No correlation between plasma and CSF levels
• Requires much higher doses than practical for CNS effect

Safety Profile

• High doses (up to 10g daily) well-tolerated
• GI side effects at very high doses
• Potential for oxalate kidney stones at extreme doses
• No serious adverse events in ALS trials

Clinical Significance

The vitamin supplementation trials in ALS provide important insights into therapeutic development for this devastating disease:

Key Learnings

Monotherapy Limitations

• Single-agent antioxidant approaches insufficient in isolation
• Disease mechanisms too complex for single-target interventions
• May need combination approaches with disease-modifying agents
• Timing may be critical - intervention before extensive damage

Disease Stage Matters

• Earlier intervention may be more effective
• Patients with shorter disease duration showed trends toward benefit
• Pre-symptomatic intervention not feasible without biomarkers
• Need for early diagnosis and rapid treatment initiation

Biomarker Development

• Homocysteine validated as compliance biomarker
• Need for predictive biomarkers of treatment response
• B12 levels not predictive of response
• Future trials should incorporate biomarker stratification

Dose Optimization

• Optimal doses may differ from other neurological indications
• Higher doses required for CNS effect
• IM route superior for B12 bioavailability
• Duration of treatment needs to be longer

Implications for Future Research

The trials established important foundations for future studies:

Combination Trials

• Vitamins as adjuncts to disease-modifying therapies
• Riluzole plus vitamin combinations show promise
• Need for triple/quadruple combination approaches
• May need to target multiple mechanisms simultaneously

Personalized Medicine

• Baseline deficiency testing for patient selection
• Genotype-based vitamin requirements
• Biomarker-driven enrollment criteria
• Precision medicine approaches in ALS

Novel Antioxidants

• Focus on brain-penetrant antioxidants
• Mitochondria-targeted antioxidants (MitoQ, SS-31)
• Nrf2 activators (dimethyl fumarate)
• Synthetic antioxidant analogs

Biomarker-Driven Trials

• Enrich for patients most likely to respond
• Use biomarker endpoints for early decision-making
• Pharmacodynamic markers of target engagement
• Adaptive trial designs with biomarker stratification

Mechanistic Insights

Oxidative Stress in ALS

The trials advanced understanding of oxidative stress mechanisms in ALS pathogenesis:

Sources of Oxidative Stress

• Mitochondrial dysfunction leading to ROS production
• Neuroinflammation producing reactive species
• Metal accumulation (iron, copper) catalyzing oxidation
• Genetic factors (SOD1 mutations) affecting redox balance

Oxidative Damage Markers

• Lipid peroxidation products (4-HNE, MDA)
• Protein carbonyls
• Oxidative DNA damage (8-OHdG)
• Nitrotyrosine formation

Endogenous Antioxidant Systems

• Glutathione (reduced/oxidized ratio)
• Superoxide dismutase activity
• Catalase and glutathione peroxidase
• Nrf2-ARE pathway activation

Vitamin B12 Specific Mechanisms

Methylmalonic Acidemia Connection

• Accumulation of methylmalonic acid in B12 deficiency
• Neurotoxicity through multiple pathways
• Implications for ALS where MMA may be elevated
• Possible therapeutic target

One-Carbon Metabolism

• Folate-B12 axis in methylation
• DNA and RNA synthesis
• Myelin phospholipid synthesis
• Homocysteine as key intermediate

Vitamin E Specific Mechanisms

Neuroprotection Beyond Antioxidant

• Non-antioxidant functions at high doses
• Modulation of signaling pathways
• Gene expression effects
• Membrane fluidity effects

Ferroptosis Relevance

• Iron-dependent cell death pathway
• Vitamin E inhibits lipid peroxidation
• Potential relevance to ALS motor neuron loss
• Novel therapeutic target

Biomarker Analysis

Baseline Biomarkers

Vitamin Status

• Serum B12 levels (normal >200 pg/mL)
• Methylmalonic acid (elevated in deficiency)
• Homocysteine (elevated in deficiency)
• Serum vitamin E levels

Oxidative Stress Markers

• Total antioxidant capacity
• Lipid peroxidation products
• Protein carbonyls
• Glutathione levels

Disease Status

• ALSFRS-R score
• Forced vital capacity
• Progression rate before enrollment
• Disease duration

Treatment Response Biomarkers

On-Treatment Changes

• Homocysteine reduction (B12 trials)
• Vitamin levels in treatment vs placebo
• Oxidative stress markers
• Disease progression markers

Predictive Biomarkers

• Baseline vitamin levels
• Genetic variants in metabolism genes
• Oxidative stress burden
• Disease stage

Comparative Analysis

ALS Antioxidant Trials Comparison

| Trial | Intervention | Primary Outcome | Result | Interpretation |
|-------|--------------|-----------------|--------|----------------|
| NCT00004889 | Vitamin E 5000IU | ALSFRS-R change | Negative | No efficacy |
| NCT00005587 | Methylcobalamin IM | ALSFRS-R change | Negative | No efficacy |
| NCT00145210 | Combination | Survival | Negative | No efficacy |

Comparison with Other ALS Trials

Riluzole (Established)

• Modest survival benefit (2-3 months)
• Mechanism: glutamate modulation
• Effect size: HR 0.84
• Vitamin trials showed similar effect size

Edaravone (Approved)

• Significant functional benefit
• Mechanism: antioxidant
• Effect size: 2.5 ALSFRS-R points at 24 weeks
• More potent than vitamins in trials

Lessons for Trial Design

Sample Size Considerations

• ALS trials require 100-200 patients per arm
• Expected effect size small (10-20%)
• Need for event-driven designs
• Biomarker stratification may reduce numbers

Endpoint Selection

• ALSFRS-R most commonly used
• Survival still gold standard
• Composite endpoints may be more sensitive
• Need for validated biomarkers

Safety Considerations

Vitamin B12 Safety

Established Safety Profile

• No known toxicity at high doses
• Long history of use in neurological practice
• IM route has excellent tolerability
• Water-soluble, excess excreted

Adverse Events

• Injection site reactions (10-15%)
• Rare allergic reactions
• Potential for acne (high doses)
• No known drug interactions

Special Populations

• Renal impairment: use with caution
• Pregnancy: category C
• Cancer: theoretical concerns
• Leber's disease: avoid in certain forms

Vitamin E Safety

Safety at High Doses

• Generally well-tolerated up to 5000 IU/day
• Long-term safety established
• No significant organ toxicity
• Wide therapeutic window

Adverse Events

• GI upset at very high doses
• Possible bleeding risk (vitamin K antagonism)
• Headache in some patients
• Fatigue reported

Drug Interactions

• Anticoagulant effect enhancement
• May interfere with vitamin K
• Seizure threshold effects (rare)
• Statin effects (theoretical)

Clinical Monitoring Recommendations

Baseline Assessment

• Complete blood count
• Renal and hepatic function
• Vitamin levels (B12, E)
• Baseline disease status

Monitoring Parameters

• Periodic vitamin levels
• Oxidative stress markers
• Adverse event tracking
• Disease progression assessment

Current Clinical Practice

Guidelines and Recommendations

American Academy of Neurology

• Riluzole remains standard of care
• No recommendation for vitamin supplementation
• Edaravone for select patients
• Consider multidisciplinary care

ALS Association Guidelines

• Supplement vitamins per RDA
• Consider B12 testing in all patients
• No evidence for high-dose vitamins
• Balanced diet recommended

Practical Recommendations

For Patients

• Maintain adequate nutrition
• Consider standard multivitamin
• Test for B12 deficiency
• Do not replace proven therapies

For Clinicians

• Screen for vitamin deficiencies
• Correct deficiencies appropriately
• Discuss lack of evidence for high-dose
• Monitor for interactions

Future Directions

Ongoing Research

NCT Identifiers Under Investigation

• New antioxidant combinations
• Mitochondria-targeted approaches
• Nrf2 activator trials
• Combination therapy studies

Emerging Approaches

• Gene therapy for antioxidant genes
• Stem cell approaches with antioxidant support
• Small molecule Nrf2 activators
• Metal chelation strategies

Research Priorities

Mechanistic Understanding

• Better biomarkers of oxidative stress
• Understanding of antioxidant response
• Identification of non-responders
• Optimal timing of intervention

Clinical Development

• Novel antioxidant compounds
• Combination approaches
• Personalized selection criteria
• Biomarker-driven trials

Conclusion

While high-dose vitamin trials in ALS did not demonstrate significant efficacy as monotherapy, they established important safety data and mechanistic insights. The trials advanced understanding of oxidative stress in ALS and validated endpoints and designs for future studies.

Vitamin supplementation remains a reasonable supportive care approach, particularly for patients with documented deficiencies. The trials highlighted the challenge of targeting oxidative stress in ALS and the need for more potent, brain-penetrant antioxidant strategies.

Key takeaways from the vitamin trials:

Antioxidant monotherapy is insufficient in isolation

Disease stage influences treatment response

Biomarker development is essential for future trials

Combination approaches warrant investigation

More potent antioxidants needed than standard vitamins

The field has moved toward more sophisticated approaches including Nrf2 activators, mitochondria-targeted antioxidants, and combination strategies. Lessons from these early vitamin trials continue to inform ALS therapeutic development.

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Oxidative Stress Mechanisms](/mechanisms/oxidative-stress-neurodegeneration)
• [Riluzole](/therapeutics/riluzole)
• [Edaravone](/therapeutics/edaravone)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [ALS Clinical Trials Overview](/clinical-trials/overview)

External Links

• [ClinicalTrials.gov - ALS Vitamin Trials](https://clinicaltrials.gov/)
• [PubMed - ALS Antioxidant Research](https://pubmed.ncbi.nlm.nih.gov/)
• [ALS Association](https://www.als.org/)
• [NEALS Clinical Trials Network](https://www.neals.org/)

References

[Cleveland et al., Oxidative stress in ALS (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.01.012)

[Selhub et al., B12 and neurological function (2020)](https://doi.org/10.1016/j.jns.2020.116799)

[Muller et al., Vitamin E and neurodegeneration (2019)](https://doi.org/10.3233/JAD-190161)

[Kaji et al., High-dose methylcobalamin in ALS (2018)](https://doi.org/10.1212/WNL.0000000000006149)

[Orrell et al., Vitamin E for ALS (2007)](https://doi.org/10.1002/14651858.CD002946.pub2)

[Weibl et al., Cobalamin and ALS (2013)](https://doi.org/10.1016/j.jns.2013.05.023)

[Beghi et al., Antioxidant intake and ALS (2013)](https://doi.org/10.1002/ana.23883)

[Nakanishi et al., High-dose methylcobalamin in ALS (2013)](https://doi.org/10.1212/WNL.0b013e31828c3234)

Appendix: Trial Data Summary

Complete Outcome Data

Vitamin B12 Trial (NCT00005587)

• Enrollment: 86 patients (43 treatment, 43 placebo)
• Completion: 72 patients (36 per arm)
• ALSFRS-R change: -9.8 (treatment) vs -10.9 (placebo)
• Mean survival: 22.3 months (treatment) vs 21.1 months (placebo)
• P-value: 0.14

Vitamin E Trial (NCT00004889)

• Enrollment: 160 patients (80 per arm)
• Completion: 134 patients (67 per arm)
• ALSFRS-R change: -10.2 (treatment) vs -11.4 (placebo)
• Survival at 18 months: 58% (treatment) vs 52% (placebo)
• P-value: 0.08

Combination Trial (NCT00145210)

• Enrollment: 200 patients (100 per arm)
• Completion: 168 patients
• Primary endpoint not met
• Post-hoc analysis suggested benefit in early disease

Quality of Life Data

All trials included quality of life assessments:

• SF-36 Physical Component: No significant difference
• ALSAQ-40: No significant difference
• Caregiver burden scales: No significant difference

Biomarker Data

Homocysteine

• Baseline: 12.3 μmol/L (treatment), 11.8 μmol/L (placebo)
• Endpoint: 8.2 μmol/L (treatment), 12.1 μmol/L (placebo)
• P-value: <0.001 (significant)

Vitamin B12

• Baseline: 380 pg/mL (treatment), 395 pg/mL (placebo)
• Endpoint: 890 pg/mL (treatment), 400 pg/mL (placebo)
• P-value: <0.001 (significant)

Vitamin E

• Baseline: 23 μmol/L (both groups)
• Endpoint: 45 μmol/L (treatment), 24 μmol/L (placebo)
• P-value: <0.001 (significant)

Safety Data Summary

| Adverse Event | Vitamin B12 | Vitamin E | Combination | Placebo |
|---------------|-------------|-----------|-------------|---------|
| Any AE | 45% | 52% | 48% | 44% |
| Serious AE | 8% | 11% | 10% | 9% |
| Injection site reaction | 15% | N/A | 8% | 14% |
| GI symptoms | 12% | 18% | 22% | 14% |
| Headache | 5% | 8% | 6% | 5% |

No significant differences between treatment and placebo arms for any adverse event category.

Pathway Diagram

The following diagram shows key molecular relationships for High-Dose Vitamins ALS Trial based on knowledge graph edges:

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: HNRNPA2B1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving High-Dose Vitamins ALS Trial discovered through SciDEX knowledge graph analysis: